• Earlier this month, Lazard Inc. disclosed that Evan Russo, CEO of Asset Management, sold 75,000 shares and also announced the appointments of Bill Young and Jean Greene as new managing directors, as well as Dmitry Shevelenko joining the board on September 2, 2025.
• The series of insider sales, including Russo's transactions totaling 200,000 shares in the past year with no insider buys, has drawn investor attention regarding management’s confidence in the company’s outlook.
• We’ll now review how this pattern of insider selling might influence the investment narrative for Lazard in light of recent analyst expectations and expansion efforts.

AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Lazard Investment Narrative Recap

To be a shareholder in Lazard right now, you would likely need to believe in the company’s ability to capitalize on continued expansion in financial advisory and asset management, especially through global growth and sector diversification. The recent insider selling, while notable, does not appear to materially affect the most important near-term catalyst: Lazard’s ability to convert its advisory backlog and expansion moves into sustained higher earnings. The biggest risk remains higher near-term costs from global expansion potentially impacting net margins.

Among recent announcements, the hiring of Bill Young and Jean Greene as managing directors for diversified industrials stands out in the context of Lazard’s ongoing business development efforts. This move underscores the firm’s short-term catalyst of bolstering its North American investment banking franchise, aiming to strengthen client coverage and revenue generation in a competitive sector.

However, investors should be aware that, regardless of new appointments, the potential for higher operating costs tied to rapid regional expansion remains a...

Lazard's outlook anticipates $4.2 billion in revenue and $620.0 million in earnings by 2028. This is based on 11.3% annual revenue growth and a $317.5 million increase in earnings from the current $302.5 million.

Uncover how Lazard's forecasts yield a $61.00 fair value, a 10% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members offered four fair value estimates for Lazard, ranging from US$47 to US$70 per share. While these opinions reflect wide differences, keep in mind that operating costs linked to Lazard’s regional growth could influence profit margins and shape the company’s near future, so explore these varied viewpoints for additional insight.

Explore 4 other fair value estimates on Lazard - why the stock might be worth as much as 26% more than the current price!

Build Your Own Lazard Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Lazard research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Lazard research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Lazard's overall financial health at a glance.

Looking For Alternative Opportunities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• These 8 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.